A randomized (open-label design), parallel group, multicentre study to evaluate the safety and tolerability of two different doses of Depigoid 34% GrassesMix, 33% Olea europaea and 33% Salsola kali a 3000 DPP/ml in subjects with allergic rhinitis or rhinoconjunctivitis, with or without controlled asthma.

Trial Profile

A randomized (open-label design), parallel group, multicentre study to evaluate the safety and tolerability of two different doses of Depigoid 34% GrassesMix, 33% Olea europaea and 33% Salsola kali a 3000 DPP/ml in subjects with allergic rhinitis or rhinoconjunctivitis, with or without controlled asthma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2015

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary) ; Olea europaea; Salsola pollen allergy immunotherapy
  • Indications Allergic rhinitis; Rhinoconjunctivitis
  • Focus Adverse reactions
  • Sponsors Laboratorios LETI
  • Most Recent Events

    • 01 Aug 2015 Status changed from recruiting to discontinued, according to European Clinical Trials Database record.
    • 06 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top